Cardiólogo y maestro en ciencias.
Instituto Nacional de Cardiología.
Cédula 12343720.
Van Gaal LF, et al. Mechanisms linking obesity with cardiovascular disease. Nature. 2006 Dec 14;444(7121):875-80.
ElSayed NA, et al. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S128-S139.
Motie M, Evangelista LS. Abstract 18300: Reduction in Blood Pressure with Weight-loss Intervention in Overweight and Obese Patients with Heart Failure. Circulation. 2014;130:A18300. Issue suppl2.
Jiménez JM, et al. Changes in Lipid Profile, Body Weight Variables and Cardiovascular Risk in Obese Patients Undergoing One-Anastomosis Gastric Bypass. Int J Environ Res Public Health. 2020 Aug 13;17(16):5858.
Selvin E, et al. The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med. 2007 Jan 8;167(1):31-9.
Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11;369(2):145-54.
Rodbard HW, et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019 Dec;42(12):2272-2281.
Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019 Aug 29;381(9):841-851.